🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Stryker Corporation (SYK)
NYSE: SYK · Real-Time Price · USD
318.15
+0.61 (0.19%)
Nov 18, 2026, 4:00 PM EST - Market closed
← View all transcripts

Jefferies Global Healthcare Conference

Nov 17, 2026

Summary

The three-year framework remains 150 bps of adjusted operating margin expansion and 70%-80% annual free cash flow, supported by operating efficiencies. Priorities include a 2027 leadership transition, recovery in Inari supply, and growth from product launches and M&A.

Matt Taylor
Analyst, Jefferies

All right. Thanks, everybody, for joining us this morning. I am Matt Taylor, here to host the first MedTech session at the London Healthcare Conference on a nice, bright, sunny day here in London. I have got the Stryker management team here with me. So we have got Spencer Stiles, President and COO, but soon to be CEO, taking over in January. And Preston Wells, the CFO and Vice President of the company. And also Nick Mead in the audience, who runs the IR function. We are going to do a fireside chat for about 25 minutes, and then we will have breakouts later here through the day.

Guys, I wanted to start off a little bit high level and maybe just talk about some of your strategic goals that were outlined at the Investor Day. You talk about growing at the high end of MedTech as one main goal, and outperforming your market. So maybe talk about how you are going to achieve that going forward and what gives you the right to win in some of your key markets.

Spencer Stiles
President and COO, Stryker

Sure. Thanks, Matt. Thanks for having us. It is super to be here. One of my goals this year was to make sure that I am spending more time with the investment community, and that included a global audience. So it is great to be in London and spending time with some international investors as well. Back to your question, our strategy remains the same. We continue to ensure that we are performing at the high end of our markets that we are playing in. We have confidence in that strategy, and that is our expectation. If we reflect back on our Investor Day we did about a year ago, that framework has not changed.

That is still the expectation for our organization as we think about sales growth, as we think about the 150 basis points of Op margin expansion on an adjusted basis. That still exists over a three-year period. That will look a little different each year. We have seen strong cash flow in the business and expect that to continue, targeting about 70%-80% free cash flow each year. So from a framework standpoint, that all still exists, and that is our expectations as we look out to the future.

Preston, I do not know if there is anything you want to add.

Preston Wells
CFO and VP, Stryker

No, I mean, you are right in terms of the framework. The framework stays the same. I think what will change, and I know we will talk a little bit about this, is as Spencer takes over, as we think about how we are going to continue that sales growth and how he is going to execute from that standpoint. But, we are just going to focus a little bit on the margin piece, and I know from the standpoint of when we laid out our expectations, the sales growth was a little bit different than what it is right now.

And while our margin is somewhat dependent on sales growth, there is so many other areas of opportunity that we have as we continue to focus on operational excellence, as we continue to look at our manufacturing facilities, how do we get more efficient in those spaces. There is plenty of opportunity for us to continue to drive that 150 basis points in EPS growth, despite what might be a little bit slower sales growth, particularly in 2026.

Matt Taylor
Analyst, Jefferies

Great. Maybe two follow-ups on that. Preston, would you start by talking about sort of the shape of the margin expansion? What are some of the key sources? Could you give us some specificity about what to expect sort of this year and next year?

Preston Wells
CFO and VP, Stryker

I mean, ideally, it would be great to kind of have it be even throughout, and so that would be the ideal way that we would like to have it. We are in that range right now for 2026. We would like to keep it that way in 2027 and 2028 and make it easy on ourselves from that perspective. But the way it looks is there are a few other things that are happening. We have a lot of things happening with regards to our facilities when we look at product transfers in particular. So how do we bring products that are currently being made outside of Stryker into Stryker? We are able to get cost savings that way. We are looking at a broader plant network optimization where we are looking at low-cost facilities.

We have two of those today. We have one in Warsaw, one in Mexico. How do we continue to drive products to those facilities? We will see bigger chunks of improvement in our gross margin in particular as we go through those types of movements. We also have other areas that we look at across our business. Think about all of the different functional areas that support, like finance, for example, the other functional pieces. We are looking at how do we streamline those parts of our business as well in support of our commercial model, which our commercial model is a little bit more expensive because of the decentralized nature of it.

We are looking at how do we get to a more efficient model to support that part of the organization, as well as the gross margin improvements that we are going to see. We really do expect to see a steady improvement, and there will be some areas that will be larger when we do some of the different plant network activities. Overall, our goal is to have that be a pretty steady cadence for the three-year period.

Matt Taylor
Analyst, Jefferies

Great. Spencer, maybe I will ask you, as you take over in the CEO role in January, what stays the same under your leadership as you take over from Kevin? What are some of the new things that you might focus on, and where do you want to put your fingerprints on Stryker?

Spencer Stiles
President and COO, Stryker

You bet. I love the question. I will start. You mentioned Kevin. I want to start by thanking Kevin. He has been an incredible leader for our organization, and really invested a lot in my own personal development, things like putting me on an external board, allowing me to sit in committee meetings. Kevin and I sort of joke back and forth that he believes I am much more prepared to step into the CEO role than he was when he joined 14 years ago, and he takes great pride in that development and growth, and just want to thank Kevin for his contributions and all he has done. As we think about the future, there are three big areas that I continue to talk to our organization about.

Number one's accelerating growth, and how do we ensure that we're in the right markets with the right strategies to continue to accelerate our growth across our, second thing I focus on, specialize and deepen our specialization in our business. Accelerating growth, deepening specialization, and the third thing I talk about is simplifying to scale. You heard Preston talk about this as we think about the scale of our organization, this specialized model that we have, the eight operating divisions, 22 different business units. How do we take things where we can scale and modernize and standardize to support that specialization? Preston mentioned some of this. If we think about our plant network, for example, it's broad and vast.

There's a way to prioritize that and put more in places that are best cost sites, where we can create more value, we can scale our systems, deploy AI. That's all an opportunity for that operational improvement. Think about it, growth, profit are sort of the three pillars there that I think about, and probably doubly for our culture, growth times two is a pretty good one. I think that's how I'm thinking about the changes. You'll probably see my fingerprints most early focused on the operating model itself, and so back to this deepening specialization, it's looking at where can we bring more focus and discipline and accountability around the various businesses we have.

That is an example of adding, for an example, a third group to focus on a specialized portion of our business, like Neurotechnology and vascular. You'll see that in our operating model evolve and shift. That'll be where I have the earliest impact in the coming months.

Matt Taylor
Analyst, Jefferies

Great. Maybe I'll just touch on, it's been kind of an odd year for Stryker with a cyberattack, some SAP implementation, some macro challenges. Maybe just talk us through any lingering effects of those things and how you think things might improve going forward with some improving Inari supply and kind of getting over the cyber issues.

Spencer Stiles
President and COO, Stryker

Yeah. We described 2026 as dynamic. There was a lot that came at us. It was incredible to see the resiliency out of our workforce and teammates, and really in cyber, the partnership from our customers and sort of that trust that they gave us as we went through a pretty choppy time. As we've shared before, we actually sort of closed the business, if you would, for a few weeks as we ran through and turned operations off and tried to make sure that our systems were ready to rock and roll as we turned them all back on. You mentioned it, as we turned the plants back on, really the one area we saw some softness in the disruption of supply was in Inari, and that we've worked very hard to get that back on track, and we're seeing that now in the fourth quarter.

Expect most of our cyber challenges really to live in 2026. As we turn the page to 2027, that'll look beyond us. Now, as we think about 2027, that it does create some comp differentials that you'll see that's a little different than normal. So I'd look at it on a full-year basis, not by quarters, as we saw that softness really in Q1. But it was a challenging year as we also saw some of the softness of the markets. We've been responding to that with a variety of things as well.

Matt Taylor
Analyst, Jefferies

Can you remind me, you talked in the beginning after the cyberattack about recapturing some procedures, but also some pent-up demand for capital, and your capital looks still strong. Can you talk about the outlook for capital after cyber?

Spencer Stiles
President and COO, Stryker

Yeah. We've been really pleased with the ongoing capital demand and CapEx across our businesses. That's continued. We saw it through the cyber event, but our customers stayed with us, and we have a pretty good line of sight. Two businesses in particular that I look at when I'm thinking about that capital environment, our medical business, where we have a variety of orders that come in that we see for our beds and stretchers business, and those probably have a lead time of somewhere between six months, sometimes the long side, nine months. That gives us a view into the future of what that capital demand looks like. And we still can't make our beds fast enough, so the demand's still there. We're working on the supply each and every day to keep up with that demand.

We haven't seen any cancellations of any orders, which is another thing that you might expect during a change like the cyber environment, but we never saw any of those cancellations. The other business is our Stryker Communications inside our endoscopy business, which does the infrastructure, beds, lights, integration equipment for operating rooms. That sometimes even has a longer time out into the future of how we think about the demand, sometimes somewhere between a year to a 1.5 year that we'll see those orders. That business has remained extremely strong in our portfolio, and we continue to see very good demand. That means there's more new operating rooms being added, more construction that we're seeing across the portfolio.

On the order side and the capital book, it remains strong, and we're seeing that again as we close out here in the fourth quarter.

Matt Taylor
Analyst, Jefferies

Maybe I'll ask about the other side of the business. In Q3, you talked about a slightly slower orthopedic market growth rate in the U.S. in hips and knees. Can you talk about what you think is causing that and how much of it is sort of macro factors versus commercial disruption and a lot of other things going on in that market?

Spencer Stiles
President and COO, Stryker

Yeah. A lot of assessment's been done, and honestly, we're still watching it as we go through all of 2026. That number one contributor, though, is a softness to the market that we are tying to the economic realities of people thinking about getting these procedures done. You might imagine on the knee side, you can delay those procedures a bit. They don't go away, so the demand's still there. It's a degenerative disease, so you see these patients eventually come back into the funnel. But they can delay if they can't take the time off, if they don't have somebody to care for them that takes the time off. We have seen some of that slowdown tied to the economy.

There have been some insurance denials as well that have come into the system, but the number one contributor to that softness, and we're estimating that in the U.S., the large joint hip and knee market's about 2.5%. That's our math right now that we're seeing in the marketplace. My guess is that won't slingshot back. You won't see it just pop right back. It'll be a gradual incline as the economy strengthens, as we go to a new year and see more of the insurance resets. Then we see some of the changes in the fourth quarter that we see where you see more people trying to get their procedures and their deductibles done, and so we're seeing some of that real time in the market as well.

Matt Taylor
Analyst, Jefferies

For a long time, Stryker's been in a strong share-taking position in hip and knee. You talked about one product gap at least, and now getting a couple other knee products out in RPS and Triathlon Gold . Maybe just talk about your confidence in getting back into a share-taking position and how those products play into that.

Spencer Stiles
President and COO, Stryker

Sure. A few comments here. First off, on the knee side, we continue to take share even in 2026. We're growing about 1.3x the market in the U.S., and it varies by other geographies across the world. We're still very pleased with that share-taking strategy. On the hip side, Matt, what you're referencing is we do have a gap in our portfolio on the impactor side. That's a hip impactor that will come out in the back half of 2027. We're really excited about that product, as you might imagine. We think that reopens the door to a variety of friendly Stryker customers that are already using parts of our portfolio that are asking for this technology. This takes a manual procedure where you're using a mallet for your impaction, and it automates that. So that's the opportunity there in front of us.

We're the world leader in power tools, so our solution that we'll come out with in the back half that we're really excited about. As I think about the portfolio in general, we remain bullish on our new products that we've entered in the joint replacement space. First off, on Mako, that's still our premium product. It drives a tremendous amount of attraction and competitive conversions. As we think about that commercial execution, as we went through the upgrade strategy from Mako 3s to Mako 4s, which we started in 2025, it really got off the ground in 2026. More of those upgrades went to what I call Stryker-friendly customers versus competitive conversions. We're repositioning some of our focus in our sales execution and sales forces across the world to really go after those competitive opportunities, so we're seeing that now with our Mako franchise.

Mako RPS, which is our handheld version of a robotic solution and combining a power tool and a robotic solution together, that's just hitting the ground now and taking off. We have exceptional feedback on that product. I just attended the American Academy of Hip and Knee Surgeons, where there was a lineup to trial that product, and we're adding more of those products into the marketplace. On the implant side, we see new product introductions that continue to build momentum with Triathlon Gold, with our MS Insert, and these are early phases. Remember, implants don't just day one skyrocket in the growth. They build over time as we bring more sets to the market, as we bring those into the doctor's use cases over and over. We'll continue to see that new product bring some of that share-taking back to the marketplace.

Matt Taylor
Analyst, Jefferies

Very good. Just to double-click on the capital question, I know it's remained strong throughout this year despite investors worried about hospital finances. Is there anything on the horizon that you see that could change or weaken the capital environment, or do you expect it to remain relatively steady?

Spencer Stiles
President and COO, Stryker

Yeah, I don't have a crystal ball. As I look out to the future, we still, as I mentioned, in the two businesses we have those longer lead times from an order standpoint. We still see that demand. As we think about, I'll call sort of the short and medium term, we expect capital demand to exist in our marketplaces across our businesses.

Matt Taylor
Analyst, Jefferies

Gotcha.

Preston Wells
CFO and VP, Stryker

Yeah, Matt, maybe one thing I would highlight in the U.S., 340B, and any impacts there, which we still are trying to assess what that means. But that could have some impact on hospitals in terms of where their financial position is. I think the good news is, as Spencer talked about before, a lot of the markets that we compete in are important for hospitals in terms of driving profitability. So, we do tend to see more of a prioritization towards the capital and the products that we have, even in those tougher situations. But that'll be something certainly that we'll be keeping an eye on in the U.S.

Matt Taylor
Analyst, Jefferies

Got it. Preston, you referenced it's going to be sort of a wonky year with a lot of the comps throughout the year. I don't know if you want to help people with their models here, but how should we think about sort of the cadence of things through the year? What would be the main puts and takes

Preston Wells
CFO and VP, Stryker

Well, the easy one will be Q1.

Matt Taylor
Analyst, Jefferies

Sure.

Preston Wells
CFO and VP, Stryker

Because we should have a very strong growth period in Q1 given the cyber event that we had in 2026. I think overall, when we think about the full year of 2026, I think what we would say is that we've got a full year in. So even anything that we missed from a cyber perspective that we expect to make up, we will have made up in 2026. We don't expect any cyber-related pushouts, if you will, into 2027. From a full-year basis, it will be a good comparison point. But certainly, the quarters will be messy. First quarter obviously will show probably stronger growth because we have a very, very soft comparable in Q1.

As we look over Q2, three, and four, it'll start to normalize a little bit, but you will see some residual hangover from cyber negatively impacting some of the growth rate. But overall, from a full-year growth perspective, it would be a good comparison point. The other thing is it'll vary by business. It'll be a little bit different kind of business to business. Certainly on the capital side where we see more capital building throughout the year, you'll have some tougher comparables, versus in some of our implant markets, you might have a little bit more easy comparable or more standard comparable.

A lot of it for 2027 is going to really be from the joint replacement or hip and knee standpoint is going to be the market, as Spencer mentioned. That's what we'll be keeping an eye on as we think about whatever our guidance is going to be in 2027.

Matt Taylor
Analyst, Jefferies

Got it. Okay. I wanted to talk about CMR. It's an exciting deal. Something that Stryker's talked about for a while, potentially getting into soft tissue robotics. I was wondering if you could kind of outline a little bit of the details of the partnership, the economics to Stryker, maybe talk about some of the milestones that you want to see to get confidence in perhaps ultimately acquiring the asset.

Spencer Stiles
President and COO, Stryker

Sure. I'll start with our first use of cash that the company still remains on M&A, and we remain bullish on our M&A pipeline and our opportunities there. As we think across our broad portfolio, there's a variety of unique spaces for growth that we're really excited about and a variety of assets that we're constantly tracking, and more to come. In particular on CMR, know that we didn't buy the company. We made a strategic investment into that organization and have set up a unique partnership of building out a U.S. sales channel for them on their behalf. The revenue for that sales in the United States won't show up at Stryker. That shows up at CMR. It'll be their sales, and we'll charge them a fee for those sales. But what it allows us to do is build our expertise and competency in the United States.

We'll hire Stryker-type people. We'll connect that to our businesses that have access to a lot of those particular customer sets. Obviously, we think this marketplace is very attractive as we think about the end markets. Maybe a little bit of our attraction to this space and then why CMR on this space, you might imagine strong end markets, but also our own competencies. We know a thing or two about robotics. We have a really strong ASC surgery center, so outpatient surgery center offense that we can build on, and we think there's a great shift of site of care. We have a world-class visualization business as well in endoscopy, so we know a lot about visualization. If you think about those core strengths, they apply well as you think about the soft tissue surgical market.

Going to CMR, why CMR? We're really impressed with their technology on the Versius and Versius Plus platform, their newest robot that they've just entered the market with. They've just received 510(k) clearance for the United States, and so that marries well with our growth and our opportunity to build that U.S. channel. The footprint, the form factor, the smaller endoscopes that are being used in that procedure, and the growth opportunity. They are the second-largest soft tissue robot market in the place, admittedly a distant number two market share position, but they currently have a strong understanding of what it takes to compete and win. As we think about this space for Stryker, we're really thinking about laparoscopic surgeons that use a straight stick endoscope right now and converting them to robotic surgery, as well as shifting site of care.

How can more of these procedures be done in the outpatient setting where we think CMR has an advantage from its form factor, its shape, its size, the modularity of it that you think will serve us well? We are excited about this. We do have an option to buy the company in the future. That is not quarters, that is not a decade. It is somewhere in between there. We will continue to monitor that and assess that, but we are really excited about this relationship that we have established with CMR. It is here up the street. It is outside London and Cambridge, and really amazing technology there, and we are excited about that future.

Matt Taylor
Analyst, Jefferies

If it does come to pass that you become the owner of CMR, maybe talk about the synergies that that could have with Stryker's other businesses and why you could be an excellent owner of that asset.

Spencer Stiles
President and COO, Stryker

Yeah, maybe I will position it this way. One of the reasons we made the investment decision we did is it is a chance for us to sort of de-risk and ensure that that business is building the right scale, both from a manufacturing standpoint, a cost standpoint, a go-to-market strategy in the areas we want. Again, we do not own the company, but we can obviously ask the right questions and watch how that grows over the time to come. We are being really thoughtful about that. We will not get into actual synergies that we expect out of this, but you might imagine those competencies and strengths I highlighted earlier, visualization, outpatient surgery, our understanding of robotics, can be applied to that type of technology in the future.

Matt Taylor
Analyst, Jefferies

I am going to use a bad word and say super cycle. It does seem like you are entering into kind of the next super cycle with a lot of the ortho products we have already talked about, CMR, and then a number of these refreshes to the MedSurg portfolio coming over the next two to three years. Sonopet, Neptune, System 10, 1888. I will not call it a super cycle. You can call it what you want.

Spencer Stiles
President and COO, Stryker

Well, you said it a few times. We like to talk about it. We have all these different businesses in our business model. We have constant innovation and new products going on at all the times in our businesses. Sometimes there is a cluster of some of these new products that come together that might feel like the word you said. But in reality, this is an expectation of our businesses that they are thinking about the needs of their customers and the new products that are required to generate that growth year in, year out. We are really excited about the new products that are coming to the market. I mentioned some in orthopedics already today, but there are many others.

As we think about our Sonopet, our next generation ultrasonic aspirator for the brain surgery and neuro, our Sonopet 3, that has received 510(k) clearance. That is now just entering the market, and we will have years of success with that product in front of us. Our next generation Neptune, our waste management system, that will enter the market in the first half of next year, Neptune 4. Could not be more excited, and the scale and footprint of that product is incredible. The amount of units that we have already installed, Neptune 3s that are installed in the United States and in Europe and in other markets across the world. A long pathway for upgrades for that product over time and a great differentiator. We are the category leaders in both of those products that I mentioned.

Then a little further down, the hip impactor in the back half of next year, and then others that you mentioned. We expect new introductions in our endoscopy business, new introductions in our power tool business. That'll come over the next couple years as well. The pipeline's strong, as it has been, and we're confident about the growth it'll generate for the organization in the future.

Matt Taylor
Analyst, Jefferies

Excellent. Maybe with the few minutes we have left, I hope to maybe double-click on Inari and talk about what needs to happen there for the supply to improve, how is it already improving, and maybe more about your aspirations, pun intended, in cardio, with IVL launching next year as well.

Spencer Stiles
President and COO, Stryker

Sure. I'll focus first on the recovery effort from the cyber issue and supply chain disruption that we experienced with Inari. As you think about the fourth quarter, we're seeing some of that more stable supply meet the demand of our customer set. We've seen some of our strongest months that we've seen all year in the last couple months, which is great to see, and we expect some of that recovery to continue here in November and December. As we turn the corner to 2027, the expectation is that supply will be meeting the demand, and this is a growth platform for our company for the future. As you know, in 2026, we acquired AVS, an IVL technology. Couldn't be more excited about the potential for that new product.

Right now, the clearance is in for the above-the-knee indication. This is a lithotripsy product that's above-the-knee indication. It's in with the FDA. We expect a clearance yet later this year. That'll kick that business off and give us a long runway for growth with that particular platform as well. As we think about 2027, 2028, and beyond, we have a phenomenal pathway to continue to grow our business in PV, as well as now thinking about how do we continue to expand across the cardiovascular space. Also, with AVS and the IVL product, we actually have started a trial in coronary. This is early days. You enroll this will take a couple years, but it gives us this access point to better understand and think about the opportunity there.

We're bullish on the end market. There's a lot of disease for this, and now we're building out a very competitive portfolio to compete in that space.

Matt Taylor
Analyst, Jefferies

Got it. Maybe I will ask you one last one on capital allocation. It is a good way to wrap up. You have talked about your goals with margin expansion, the strong cash flow, but a very M&A-forward mindset. How should we think about the cadence of M&A and how you balance that with some other ways of returning cash to shareholders, like buybacks?

Spencer Stiles
President and COO, Stryker

Our prioritization still number one is M&A, so we will deploy our capital in M&A. We have more recently entered in a share buyback program, which we have executed some of that this year. You will see us do that in a small way moving forward in 2027 and beyond, really with a focus on offsetting some of the dilution in our organization. The third area, we will still continue to pay our dividend, and we will modestly grow that over time. That is sort of, I think, about the capital outlay for the business. That is how we think about it. Back on the M&A, to your question, we remain really bullish about the pipeline that exists. We have mentioned this, and a lot of this has not changed.

I have been leading our M&A function in the business for years, and so I have a lot of understanding of what that pipeline looks like, and we will carry that forward. You can think about places like HIT, healthcare information technology, as a very attractive market, a place we have deployed. We will continue. There are lots of assets that we think can accelerate growth. Men's and women's health, and that is inside our endoscopy business. Outstanding opportunities there. Pelvic health, urology, things like that. Great, exciting assets that we are looking at. We talked about soft tissue robotics. That remains an attractive space. We will continue to look at other areas there. We look at Neurotechnology.

I think it is one of the great growth platforms. The disease state is massive. Unfortunately, the incident rate continues for tumors. As we think about how we can complement that Neurotechnology business over time, that is another really important area. I do want to think about these more as in tuck-ins. Our company is bigger, so they are likely a little bigger tuck-ins. That will continue to be our primary focus of the type of deals that we are looking after, with the intention that it will accelerate growth for our organization over time.

Matt Taylor
Analyst, Jefferies

Great. Well, that's a great run-through. Thanks, guys. Thanks so much.

Spencer Stiles
President and COO, Stryker

Thanks for having us. Thank you, everybody.

Matt Taylor
Analyst, Jefferies

Thanks for your interest.